Sofosbuvir for treating chronic hepatitis C - guidance (TA330)

NICE Accredited

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
25 February 2015

Abstract

Sofosbuvir (also known as Sovaldi) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C. It is taken with other drugs (peginterferon alfa and ribavirin, or ribavirin alone). See table 1.

Table 1 Sofosbuvir treatment

Type of hepatitis C Sofosbuvir with peginterferon alfa and ribavirin Sofosbuvir with ribavirin alone
Genotype 1 Recommended by NICE Not recommended by NICE
Genotype 2 Not licensed

Recommended only if:

  • the person’s hepatitis C has not been treated before and they cannot have interferon or
  • the person’s hepatitis C has been treated before but has not responded well enough.
Genotype 3

Recommended only if:

  • the person’s hepatitis C has not been treated before and they have cirrhosis or
  • the person’s hepatitis C has been treated before but has not responded well enough.
Recommended only if the person has cirrhosis and cannot have interferon.
Genotype 4, 5 or 6 Recommended only if the person has cirrhosis. Not recommended by NICE

What does this mean for me?

If sofosbuvir (with peginterferon alfa and ribavirin, or ribavirin alone) is recommended for you and your doctor thinks that it is the right treatment, you should be able to have the treatment on the NHS.

If you are not eligible for treatment as described above, you should be able to continue taking sofosbuvir (with peginterferon alfa and ribavirin, or ribavirin alone) until you and your doctor decide it is the right time to stop.